MindBio Therapeutics Corp., together with its subsidiaries, operates as a clinical stage drug development company in Australasia. The company engages in researching, developing, and testing microdosing of psychedelic substances as a potential treatment for the management of various mental health conditions, such as depression, anxiety, chronic pain, cognitive impairment, post-traumatic stress disorder, panic disorder, and opiate addictions. It also establishes and executes research protocols through formal clinical trials that are facilitated via digital therapeutic platforms; and invests in research for developing treatments for depression, anxiety, PTSD and chronic pain. In addition, the company develops MB22001, which is in Phase 2 clinical trial, for the treatment of major depressive disorder, as well as existential distress, anxiety, and depression associated with advanced stage cancer; and wearable devices to collect biometric data in mental health patients taking psychedelic medicines. MindBio Therapeutics Corp. was incorporated in 2021 and is headquartered in Vancouver, Canada.
Metrics to compare | MBIO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMBIOPeersSector | |
---|---|---|---|---|
P/E Ratio | −4.3x | −0.5x | −0.5x | |
PEG Ratio | −0.18 | 0.00 | 0.00 | |
Price/Book | −1.2x | 0.7x | 2.6x | |
Price / LTM Sales | −11.0x | 0.8x | 3.2x | |
Upside (Analyst Target) | - | 52.8% | 40.5% | |
Fair Value Upside | Unlock | 19.9% | 4.4% | Unlock |